Online inquiry

IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11834MR)

This product GTTS-WQ11834MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11834MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11986MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ2195MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ3585MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ13129MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ12204MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ6017MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ3324MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ8697MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-TF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW